Isabel Marzo
Overview
Explore the profile of Isabel Marzo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1085
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cytofluorometric assessment of calreticulin exposure on CD38 plasma cells from the human bone marrow
Beltran-Visiedo M, Serrano-Del Valle A, Jimenez-Alduan N, Soler-Agesta R, Naval J, Galluzzi L, et al.
Methods Cell Biol
. 2024 Oct;
189:189-206.
PMID: 39393883
Exposure of the endoplasmic reticulum chaperone calreticulin (CALR) on the surface of stressed and dying cells is paramount for their effective engulfment by professional antigen-presenting cells such as dendritic cells...
2.
Beltran-Visiedo M, Jimenez-Alduan N, Diez R, Cuenca M, Benedi A, Serrano-Del Valle A, et al.
Mol Oncol
. 2023 Sep;
17(12):2507-2525.
PMID: 37704591
A better understanding of multiple myeloma (MM) biology has led to the development of novel therapies. However, MM is still an incurable disease and new pharmacological strategies are needed. Dinaciclib,...
3.
Gil-Moles M, Olmos M, Monge M, Beltran-Visiedo M, Marzo I, Lopez-de-Luzuriaga J, et al.
Chemistry
. 2023 Mar;
29(37):e202300116.
PMID: 36924425
Silver complexes bearing substituted terpyridine or tetra-2-pyridinylpyrazine ligands have been prepared and structurally characterised. The study of the anticancer properties of silver complexes with this type of ligands is scarce,...
4.
Gonzalo O, Benedi A, Vela L, Anel A, Naval J, Marzo I
Cells
. 2023 Mar;
12(5).
PMID: 36899936
Evasion of apoptosis is one of the hallmarks of cancer cells. Proteins of the Bcl-2 family are key regulators of the intrinsic pathway of apoptosis, and alterations in some of...
5.
Serrano Del Valle A, Beltran-Visiedo M, de Poo-Rodriguez V, Jimenez-Alduan N, Azaceta G, Diez R, et al.
Oncoimmunology
. 2022 Nov;
11(1):2141973.
PMID: 36338146
Immunogenic cell death (ICD) has been proposed to be a crucial process for antitumor immunosurveillance. ICD is characterized by the exposure and emission of Damage Associated Molecular Patterns (DAMP), including...
6.
Soler-Agesta R, Guerrero-Ochoa P, Marco-Brualla J, Ibanez-Perez R, Marzo I, Martinez-Lostao L, et al.
Int J Mol Sci
. 2022 Aug;
23(15).
PMID: 35955839
Nine kDa granulysin (GRNLY) is a human cytolytic protein secreted by cytotoxic T lymphocytes (CTL) and NK cells of the immune system whose demonstrated physiological function is the elimination of...
7.
Guerrero-Ochoa P, Ibanez-Perez R, Berbegal-Pinilla G, Aguilar D, Marzo I, Corzana F, et al.
Biomedicines
. 2022 Jun;
10(6).
PMID: 35740244
Two granulysin (GRNLY) based immunotoxins were generated, one containing the scFv of the SM3 mAb (SM3GRNLY) and the other the scFv of the AR20.5 mAb (AR20.5GRNLY). These mAb recognize different...
8.
Akesolo O, Buey B, Beltran-Visiedo M, Giraldos D, Marzo I, Latorre E
Biochem Pharmacol
. 2022 Mar;
199:114992.
PMID: 35292256
Despite recent biomedical improvements in treating multiple myeloma, this disease still remains incurable. Toll-like receptors (TLRs) are key immune receptors that recognize conserved molecular patterns expressed by pathogens and damaged...
9.
Reina-Ortiz C, Giraldos D, Azaceta G, Palomera L, Marzo I, Naval J, et al.
Cells
. 2022 Feb;
11(3).
PMID: 35159200
Natural killer (NK) cell-based therapies have emerged as promising anticancer treatments due to their potency as cytolytic effectors and synergy with concurrent treatments. Multiple myeloma (MM) is an aggressive B-cell...
10.
Allende-Vega N, Brualla J, Falvo P, Alexia C, Constantinides M, Faydherbe De Maudave A, et al.
Sci Rep
. 2022 Jan;
12(1):1341.
PMID: 35079096
Solid tumor cells have an altered metabolism that can protect them from cytotoxic lymphocytes. The anti-diabetic drug metformin modifies tumor cell metabolism and several clinical trials are testing its effectiveness...